We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing... Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. Show more
Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at...
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation...
Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.68 | -12.746585736 | 13.18 | 13.59 | 11.5 | 101663 | 12.9194985 | CS |
4 | 0.25 | 2.22222222222 | 11.25 | 16 | 10.8276 | 68023 | 13.36160894 | CS |
12 | 1.62 | 16.3967611336 | 9.88 | 16 | 6.84 | 36415 | 11.82002971 | CS |
26 | 1.88 | 19.5426195426 | 9.62 | 16 | 6.84 | 25001 | 11.67979054 | CS |
52 | -10.004 | -46.521577381 | 21.504 | 34.46 | 3.9501 | 3763877 | 14.76746556 | CS |
156 | -499.7 | -97.7503912363 | 511.2 | 1711.2 | 3.9501 | 7941847 | 36.52489526 | CS |
260 | -677.3 | -98.3304297329 | 688.8 | 1711.2 | 3.9501 | 7394638 | 39.31635151 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions